TL;DR
Get beauty and skincare favorites delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Hair-loss products in the UK grew by 32% in the year to the end of August, as use of GLP-1 medicines also rose, according to Worldpanel by Numerator. A recent BMJ study identified an association between GLP-1 drugs and increased hair-loss risk, but researchers described the absolute risk as low; the sales data do not establish that the medicines caused the increase.
UK sales of hair-loss products grew 32% in the year to the end of August, according to Worldpanel by Numerator, as use of GLP-1 weight-loss medicines increased and research drew attention to possible hair loss as a side effect. The figures point to rising consumer interest, but do not show that the drugs caused the sales increase or that every user faces hair loss.
Worldpanel by Numerator estimated that 6.3% of Great British households used GLP-1 medicines in 2026, up from 4.1% in 2025 and 2.3% in 2024. The source report does not specify the exact survey dates or provide further detail on how household use was measured. The medicines named include semaglutide and tirzepatide products such as Ozempic, Wegovy and Mounjaro.
The Cosmetics Business report also cites a recent study published in the British Medical Journal that identified a link between GLP-1 drugs and increased risk of hair loss. It says the researchers characterized the absolute risk as low. That finding indicates an association, not proof from the information provided that the medicines directly cause hair loss in individual patients.
The same report says Novo Nordisk, the maker of Ozempic, recently announced an intention to enter the hair-loss treatment market. It provides no details on a product, development timetable or regulatory plans. The sales growth, research finding and company announcement together suggest increased attention to hair loss, but the available information does not establish how much each factor contributed.
Weight-Loss Drugs Meet Hair Care
The figures connect two fast-growing areas of consumer health: use of medicines for weight management and demand for products marketed for thinning or shedding hair. For readers using or considering these medicines, the BMJ finding makes hair loss a potential side effect to discuss with a clinician, rather than a confirmed outcome for all patients. The report’s low absolute-risk characterization also matters: an increased relative risk does not by itself indicate that the outcome is common.
For the hair-care industry, the sales estimate and Novo Nordisk’s stated interest signal commercial attention to the issue. But product sales are not a measure of how many people experience medication-associated hair loss, and the source provides no evidence that hair-loss products prevent or treat a drug-related effect. Consumers should distinguish products marketed for thickening or strengthening from treatments supported for a specific cause of hair loss.
Products Worth Considering
Theragun Mini 3rd Generation Massage Gun – Travel Essential (Black)
Hyperice Normatec 3 Leg Compression Boots – Standard Size
OMRON Complete 2-in-1 Upper Arm Blood Pressure Monitor with EKG
As an affiliate, we earn on qualifying purchases.
Rising Use, Longstanding Products
Volumising, thickening and strengthening products, as well as treatments marketed for hair loss and thinning, predate the current growth in GLP-1 use. The development described in the Cosmetics Business report is not the arrival of a new category, but a possible change in demand as medicines such as semaglutide and tirzepatide become more widely used.
According to Worldpanel by Numerator figures cited in the report, the share of Great British households using GLP-1 medicines climbed from 2.3% in 2024 to 4.1% in 2025 and 6.3% in 2026. Separately, hair-loss product sales were up 32% over the year to the end of August. The source suggests the trends may be related, but supplies no direct consumer survey or other evidence establishing a causal link between increased medicine use and product purchases.
“Use in Great Britain rose from 2.3% of households in 2024 to 4.1% in 2025 and 6.3% in 2026.”
— Worldpanel by Numerator, as cited by Cosmetics Business
Cause, Risk and Sales Drivers
The information supplied does not identify the BMJ study’s design, participant numbers, size of the risk increase or the specific medicines examined. It is therefore not possible from this report alone to assess the study’s methods or determine how its findings apply to particular patients. The source says the study found a link and that absolute risk was low; it does not establish direct causation.
It is also unclear whether GLP-1 use drove the 32% rise in hair-loss product sales. The sales figure has no stated comparison with other possible influences, such as wider interest in hair care, and no baseline breakdown by product type or purchaser. The report does not say what treatment Novo Nordisk may develop, when it could be available, or whether the company has begun clinical development.
Evidence and Product Plans
Further detail on the BMJ study—including its methods and the size of the reported risk—would help patients and clinicians interpret the association. People taking or considering GLP-1 medicines who notice hair loss can raise it with their prescribing clinician, who can consider individual circumstances and other possible causes. The available source does not advise stopping or changing prescribed treatment.
On the commercial side, the next significant information would be any specifics from Novo Nordisk about its proposed hair-loss treatment, including its target condition, development stage and timeline. Updated sales and household-use data could also show whether the trends continue, but would not alone prove that one caused the other.
Key Questions
Does this report prove GLP-1 medicines cause hair loss?
No. The cited BMJ study identified a link with increased risk, but the source does not describe evidence establishing direct causation. It also says the absolute risk is low.
How much did UK hair-loss product sales increase?
Worldpanel by Numerator estimated that sales grew by 32% in the year to the end of August. The report does not provide a longer trend or a breakdown by product.
How common is GLP-1 use in Great Britain?
Worldpanel by Numerator estimated household use at 6.3% in 2026, compared with 4.1% in 2025 and 2.3% in 2024. These are household-use estimates, not the share of individual people taking the medicines.
Is Novo Nordisk launching a hair-loss treatment?
The report says the company announced an intention to enter the hair-loss treatment market. It does not provide a product name, launch date or development details.
Source: cosmeticsbusiness.com
